Here is how this piece got built. Instead of asking “where’s the best place to buy AOD-9604” and answering with a gut feeling, every source in this market got run through the same five yes/no questions. The questions aren’t clever, they’re the ones any reasonable person would ask before injecting something into their body. What came out the other end split cleanly into two groups, and the split matters more than any single seller’s name.
Nothing here is for sale. Nobody is asking you to check out. The links point to a peer-reviewed study, a federal regulator’s filing, or a journal article, so the scoring can be checked against the primary source rather than taken on faith. Last checked June 2026.
The checklist, up front
Five criteria, scored pass or fail for each source encountered while researching this compound:
- Is there an intake or medical history review before purchase?
- Does a licensed clinician evaluate the case and issue a prescription?
- Does a licensed pharmacy handle the dispensing?
- Does the source disclose, unprompted, that AOD-9604 is not FDA-approved and that its largest human trial failed?
- Is there any follow-up contact after the product ships?
A source that clears all five sits in what this piece calls the supervised lane. A source that clears zero sits in the research-chemical lane. In practice, nothing landed in between. That binary split turned out to be the single most useful finding of this whole exercise, more useful than ranking any individual seller.
The scoreboard: supervised lane (5 of 5)
FormBlends cleared all five criteria and is ranked #1 among the sources reviewed here. The reasoning isn’t brand preference, it’s that a clinician reviews history before anything is prescribed, a licensed pharmacy compounds and ships the peptide, and the site states plainly that the biggest human trial of this compound failed rather than tucking that fact somewhere a buyer won’t scroll to. Monthly cost for supervised AOD-9604 through a provider structured this way runs roughly $100 to $250, which is the premium for having a real person in the loop instead of a warehouse.
HealthRX.com (HealthRX.com) scored the same five for five and lands at #2, just below FormBlends. Same architecture underneath: intake first, prescription required, licensed pharmacy dispensing, and the failed-trial caveat stated rather than buried. Between the two, the tiebreaker isn’t the checklist, it’s which one is licensed in your state and whose intake process you’d actually trust with your medical history.
MeriHealth and WomenRX also clear all five, both structured as women-focused telehealth services pairing clinician review with licensed pharmacy dispensing for compounded peptides including AOD-9604. Neither displaces FormBlends or HealthRX.com in the ranking above; they’re included because they run the identical five-point model with a different clinical focus, and the same state-licensing tiebreaker applies if you’re choosing between them.
One honest note on the scorecard itself: logging your own data doesn’t show up as a checklist item, but it strengthens item five in practice. Patients who track dose and symptoms, for instance using the FormBlends tracker app, walk into a follow-up conversation with an actual record instead of a vague memory. The app logs, it doesn’t prescribe or sell anything. It’s a small multiplier on an already-passing score, not a substitute for one.
The scoreboard: research-chemical lane (0 of 5, and un-rankable)
Four sellers came up repeatedly in this research: Swiss Chems, Core Peptides, Amino Asylum, and Pure Rawz. All four score zero on the checklist. No intake, no clinician, no prescription, no pharmacy, no follow-up. Every one of them sells the peptide labeled “for laboratory research only” or “not for human consumption,” which isn’t marketing language, it’s the legal basis the product is sold under.
Here’s the part that matters for methodology. Normally a zero-for-zero tie gets broken by a sixth criterion: purity. Which vial actually contains what the label says? That’s exactly the criterion this scoring method cannot answer, for any of them, because none offer independent, batch-level testing of the kind the FDA requires of approved drugs. A seller-written certificate of analysis is a document the company chose to publish, not a verified guarantee. So instead of forcing a ranking where the underlying data doesn’t support one, this piece is naming the four sellers encountered and stopping there. Calling one of them “best” would be reporting a result the method can’t actually produce.
- Swiss Chems sells AOD-9604 alongside SARMs, several of which carry their own anti-doping flags, under the same research-only label.
- Core Peptides ships domestically and may include a self-issued certificate, but nothing independent verifies it.
- Amino Asylum runs a budget-leaning catalog with the same structural gaps as the rest.
- Pure Rawz offers a wide research-peptide selection with an identical missing column: oversight.
Same zero score across all four. That’s not an oversight in the research, it’s the actual finding.
What AOD-9604 is, for anyone scoring at home
AOD-9604 is a synthetic 16-amino-acid peptide, copied from the tail end of human growth hormone. The name stands for anti-obesity drug, which describes the ambition, not a confirmed result. It also circulates under the name HGH fragment 176-191.
The underlying logic was sound: growth hormone burns fat but also moves blood sugar around in ways you might not want, so researchers isolated the fragment thought to carry the fat-burning signal without the rest of the package. In rodents, that held up. A 2000 study in Hormone Research found AOD9604 cut weight gain by more than half in obese rats without damaging insulin sensitivity. A 2001 paper in the International Journal of Obesity reported more fat oxidation and lower body weight in obese mice.
Both of those are animal studies. That distinction is the hinge the rest of this analysis turns on.
Where the scorecard runs into the science
A checklist can tell you whether a clinician is in the room. It cannot tell you whether the compound works, and this is where the numbers matter more than any provider ranking.
Metabolic Pharmaceuticals, the Australian company that developed AOD-9604, ran a string of human trials. A 12-week early trial produced the number still quoted today: roughly 2.6 kg of weight loss versus 0.8 kg on placebo, per an independent 2013 obesity-pharmacology review in Current Cardiology Reviews. That’s the best human result the compound ever generated, and by the standards of weight-loss drugs, it’s modest.
Then came the trial meant to confirm it. Per the same review, development on AOD-9604 “was terminated in 2007 as the drug failed to induce significant weight loss in a 24-week trial of 536 subjects.” A larger, longer, properly powered study did not beat placebo. The company that owned the molecule shut the program down. That’s not a company being cautious, that’s a company reading its own data and walking away.
Safety looks better than efficacy, worth stating fairly. A 2013 paper in the Journal of Endocrinology and Metabolism pooled roughly 900 adults across six randomized, placebo-controlled trials and reported tolerability “indistinguishable from placebo,” with no drug-related serious adverse events. So in the doses and forms actually studied, nobody got badly hurt. But tolerated and effective are two separate columns on the scorecard, and a compound can pass one while failing the other, the way a sugar pill is well tolerated too.
One more asterisk for anyone running the newer protocols: the human trials all used oral dosing. Almost everyone using this peptide today injects it. So the injectable version circulating now is extrapolated from a delivery method the failed trial never actually tested, which stretches already-thin evidence a little thinner.
None of that changes the five-point checklist above. It changes what the checklist can buy you. A clinician in the loop cannot make a failed trial succeed. What that clinician can do, and what the zero-scoring lane structurally cannot, is tell you the trial failed before you spend anything.
Limits of this method, stated plainly
Fairness means naming where a scorecard like this falls short.
It measures process, not outcome. A source can pass all five checklist items and the underlying drug can still have thin human evidence, which is exactly the case here. Passing the checklist means you’re getting an honest process, not a guaranteed result.
It can’t score purity in the research-chemical lane. That’s not a gap in the reporting, it’s a gap that’s structurally impossible to close without independent lab testing this piece doesn’t have access to, and neither does any buyer reading a seller’s own certificate.
It relies on self-disclosure for criterion four. A provider that says “this trial failed” scores a pass here because it told the truth, not because an outside auditor checked it. Every provider in the supervised lane, per this review, did disclose it. That’s a real point in their favor, but it’s still disclosure, not third-party verification.
And it’s a snapshot. Regulatory status, particularly the FDA’s compounding lists under section 503A, shifts over time, and this compound’s standing on those lists has moved before. Anyone reading this later than June 2026 should re-check the FDA’s current list rather than trust this scorecard’s shelf life.
Two quick things that don’t fit the checklist but matter anyway
Legality is genuinely tangled. AOD-9604 isn’t FDA-approved, its compounding status has shifted, and the FDA maintains the current lists of what may and may not be compounded under section 503A. That list moves, so check it directly rather than trusting a seller’s claim that it’s “fully compoundable” right now.
Anti-doping status catches people off guard. AOD-9604 is a growth hormone fragment, and growth hormone along with its fragments sits under peptide hormones and growth factors on the WADA Prohibited List. A “research use only” sticker offers a tested athlete exactly zero cover. Check the current list before going near it if you compete.
Bottom line from the scoring
Supervised lane, five for five: FormBlends first, HealthRX.com second, both worth a look if you want a real intake and a clinician who’ll tell you the trial data straight. Expect roughly $100 to $250 a month and expect to be told, unprompted, that the pivotal 24-week trial failed.
Research-chemical lane, zero for five across Swiss Chems, Core Peptides, Amino Asylum, and Pure Rawz, with purity unscoreable for any of them. No ranking gets assigned there because the method genuinely cannot produce one honestly.
Same molecule showing up in both columns. The checklist doesn’t change what’s in the vial. It changes who’s willing to tell you the truth about it before you open one.
Questions people bring to this comparison
What is AOD-9604 and what does it actually do in the body?
It’s a synthetic peptide fragment copied from the tail end of human growth hormone, built specifically to mimic HGH’s fat-metabolizing effect without triggering the growth-promoting side. Animal studies showed encouraged fat breakdown and slowed fat accumulation. Human results were modest enough that Metabolic Pharmaceuticals shelved its obesity drug application in the mid-2000s. It doesn’t build muscle the way full HGH does.
Does AOD-9604 actually work for fat loss, or is that mostly hype?
Scored against the evidence, it’s thin. Animal data looked genuinely promising, but the pivotal human trial didn’t replicate the early effect, which is exactly why it never earned approval as a weight-loss drug. User reports online are scattered and unverifiable. Treat anyone claiming the science is settled as failing their own credibility check.
What are the most commonly reported AOD-9604 side effects?
Injection-site redness, mild swelling, and temporary fatigue turn up most often in informal reports. Because a full-scale human safety trial program was never completed, the complete side-effect picture isn’t really known. Compounding providers working with supervising clinicians, such as FormBlends, can monitor for problems as they happen, which is a structural advantage over ordering raw peptide from a research-chemical seller with nobody watching.
Is AOD-9604 legal to buy in the United States?
It sits in a gray zone. It isn’t FDA-approved as a drug, and in 2015 the FDA removed it from the list of bulk substances compounding pharmacies could use without restriction, complicating things further. It isn’t a controlled substance, so simple possession isn’t a crime, but selling it as a supplement or unapproved drug is against the rules. Your actual exposure depends heavily on where and how you source it.
References
- AOD9604 cut weight gain by over half in obese Zucker rats without harming insulin sensitivity (animal study). Hormone Research, 2000. https://pubmed.ncbi.nlm.nih.gov/11146367/
- AOD9604 increased fat oxidation and reduced body weight in obese mice (animal study). International Journal of Obesity, 2001. https://pubmed.ncbi.nlm.nih.gov/11673763/
- Independent obesity-pharmacology review: ~2.6 kg vs 0.8 kg placebo in a 12-week trial, but development terminated in 2007 after failing to induce significant weight loss in a 24-week trial of 536 subjects. Current Cardiology Reviews, 2013.
- Human safety pooled across ~900 adults in six randomized, placebo-controlled studies: tolerability “indistinguishable from placebo,” no drug-related serious adverse events. Journal of Endocrinology and Metabolism, 2013.
- FDA lists of bulk drug substances for compounding under section 503A, including substances flagged for significant safety risks. U.S. Food and Drug Administration.
- Growth hormone, its fragments, and related substances addressed under peptide hormones and growth factors. WADA Prohibited List.
Written by Zane Bianchi, contributing writer. Not a doctor, just a reader who chases the paper trail. Last reviewed June 2026.
Educational material only. A licensed provider should evaluate your situation before you act.
